Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at … pharmaceutical innovation increased mean age at death by 0.87 years (10.4 months) - about 44% of the total increase in longevity … pharmaceutical innovation. The baseline estimate of the cost per life-year gained from pharmaceutical innovation in Greece is $17 …

I analyze the effects of four types of medical innovation and cancer incidence on US cancer mortality rates during the … pre‐dated factors that drove both innovation and mortality and that there would have been parallel trends in mortality in … the absence of innovation, the estimates indicate that there were three major sources of the 13.8% decline of the age …